Brazilian Liquid-Crystal Nanoparticles Advance Topical siRNA Silencing of TNF-Alpha in Psoriasis, But Preclinical Data Leave Efficacy and Scalability Questions Open

The MedicalXpress report on Maria Vitória Bentley’s FAPESP Week London presentation describes 20 years of work at USP’s NanoGeneSkin lab developing lipid nanoparticles that encapsulate siRNA to degrade messenger RNA for overexpressed cytokines such as TNF-alpha. This builds on established RNA-interference principles yet remains at the formulation and ex-vivo penetration stage, with no human pharmacokinetic or efficacy data disclosed. Existing systemic anti-TNF biologics reduce PASI scores by 75-90% in phase-3 RCTs of 1,000-plus patients but carry black-box infection warnings; a topical nanoparticle route could theoretically limit exposure, yet the presentation omits head-to-head barrier-penetration metrics against microneedle or electroporation alternatives already tested in small (n<50) human studies. Parallel work published in Journal of Controlled Release (2021, observational cohort n=28) showed modest downregulation of IL-17 with similar lipid carriers, but lacked randomization and reported 40% inter-subject variability in stratum-corneum retention. Conflicts of interest are unstated for the INCT consortium, which receives public funding. Overall, the platform represents incremental delivery engineering rather than a completed therapeutic, underscoring the gap between elegant nanoparticle architecture and the large-scale RCTs required for regulatory approval in a 190-million-patient population.